Enterprise Value
259M
Cash
117.1M
Avg Qtr Burn
-27.51M
Short % of Float
0.00%
Insider Ownership
45.43%
Institutional Own.
20.83%
Qtr Updated
03/31/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
COMP360 (Psilocybin) Details Treatment Resistant Depression | Phase 3 Data readout | |
COMP360 (Psilocybin) Details Post-traumatic stress disorder (PTSD) | Phase 2 Data readout | |
COMP360 (Psilocybin) Details Anorexia nervosa | Phase 2 Interim update |